A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery
Launched by UCB PHARMA · Jan 3, 2008
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject has idiopathic Parkinson's disease (early- or advanced-stage), as defined by the cardinal sign bradykinesia, plus the presence of at least one of the following: resting tremor, rigidity, or postural instability and is without any other known or suspected cause of Parkinsonism.
- • Subject is scheduled for an operation requiring general anesthesia.
- Exclusion Criteria:
- • Subject has previously been treated with rotigotine.
- • Subject has a history of significant skin hypersensitivity to adhesives or other transdermals or recent unresolved contact dermatitis or has a known allergy or hypersensitivity to rotigotine or to other components of the patch.
- • Subject is scheduled for a surgical procedure (surgery per protocol(SPP)) that requires magnetic resonance imaging or cardioversion.
- • Subject has a high probability to require extended postoperative ventilation (\> 24 hours).
- • Subject has any medical condition that, in the opinion of the investigator, could jeopardize or compromise the subject's ability to participate in this trial.
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Augsburg, , Germany
Ulm, , Germany
Bremerhaven, , Germany
Dresden, , Germany
Bonn, , Germany
Kiel, , Germany
Bochum, , Germany
Stralsund, , Germany
Dortmund, , Germany
Schwerin, , Germany
Hanau, , Germany
Ingolstadt, , Germany
Patients applied
Trial Officials
UCB Clinical Trial Call Center
Study Director
+1 877 822 9493 (UCB)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials